Targeted Protein Degradation in Clinical Trials: The Promise of PROTACs and Molecular Glues Targeted protein degradation (TPD) has emerged as a promising therapeutic approach, with several drugs currently in clinical trials. Proteolysis-targeting chimeras (PROTACs) and molecular glues are the two main classes of TPD drugs. As of 2025, there are multiple PROTAC candidates in clinical […]
Targeted Protein Degradation in Clinical Trials: The Promise of PROTACs and Molecular Glues Targeted protein degradation (TPD) has emerged as a promising therapeutic approach, with several drugs currently in clinical
In a recent study reported in the journal Molecular Therapy, a team led by researchers from the University of Science and Technology of China, Hefei, presents a groundbreaking approach
Introduction Degrader Antibody Conjugates (DACs) represent a revolutionary therapeutic modality that combines the precision of monoclonal antibodies (mAbs) with the potent protein degradation capabilities of targeted protein degraders, such as
Press Release | Marin Biologic Labs Achieves Flawless FDA Inspection for Second Consecutive Year, Expands Biopharmaceutical Services What are PROTACs? Proteolysis Targeting Chimeric (PROTAC) drugs are innovative molecules that utilize
With over 30 years of expertise in cell-based potency assay development, we deliver precise, GMP-compliant potency assays for PROTACs, molecular glues, and other TPD drug candidates to accelerate your clinical
With over 30 years of expertise, we specialize in providing assay services essential for targeted protein degradation (TPD) drug development, preclinical studies, IND/BLA applications, and commercialization. Click here to learn
What is a Cell Based Assay? A cell based assay uses live cells to quantify biological processes and evaluate cellular responses to various stimuli. These assays provide a more physiologically
Lung cancer is among the most lethal malignancies worldwide, with limited therapeutic success despite advancements in immunotherapy. Immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1 pathways, have marked a paradigm
A groundbreaking study published in the journal Cell has unveiled a pivotal role for the immune system in suppressing the spread of breast cancer (1). The research highlights how
Researchers from the German Cancer Research Center (DKFZ), CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, and Heidelberg University Medical Faculty have developed an innovative proteomic
